Oncology
Oncology
Advertisement
Chadi Nabhan, MD, MBAHealthcare Unfiltered | December 5, 2023
Dr. Allison Rosenthal talks about her leukemia survivorship journey and how she advocates for AYA patients with cancer.
Listen Now
Rob DillardConference Coverage | December 5, 2023
In vivo T-cell depletion with antithymocyte/antilymphocyte globulin prior to HSCT is effective at reducing GVHD.
Rob DillardConference Coverage | December 5, 2023
Treating myelofibrosis patients with ruxolitinib before, during, and after HSCT is safe and effective.
Rob DillardConference Coverage | December 4, 2023
Persistence of cells with MF-associated driver mutations following allogeneic HSCT was linked to outcomes.
Rob DillardConference Coverage | December 4, 2023
Ropeginterferon alfa-2b is an effective treatment for patients with primary myelofibrosis in the pre-/early fibrotic stage.
Rob DillardConference Coverage | December 1, 2023
Hemoglobin and platelets are associated with overall survival in patients with myelofibrosis following allogeneic HSCT.
Rob DillardConference Coverage | November 30, 2023
Treatment-naïve myelofibrosis patients who received navitoclax plus ruxolitinib saw a significant reduction in spleen ...
The Fellow on CallThe Fellow on Call | November 28, 2023
The Fellow on Call group discusses the fundamentals of chemotherapy, including basic terminology, optimal dosing, and more.
Rebecca AraujoBreast Cancer | November 16, 2023
For patients with breast cancer, a regimen of epirubicin followed by adjuvant chemotherapy is associated with worse QOL.
Healthcare UnfilteredHealthcare Unfiltered | November 9, 2023
Drs. Chadi Nabhan and Jennifer Mack discuss the delicate art of delivering bad news to patients with cancer.
Healthcare UnfilteredHealthcare Unfiltered | October 31, 2023
Moshe Chasky and Allen Lord Terzian, of Alliance Cancer Specialists, join Dr. Chadi Nabhan to discuss a high-stakes lawsuit.
Rob DillardBreast Cancer | October 31, 2023
Drs. Vishwas Paralkar and Sophia Gayle discuss CBX-15, a novel therapy for triple-negative breast cancer.
The Fellow on CallThe Fellow on Call | October 30, 2023
The group discusses chimeric antigen receptor T-cell therapy, bispecific T-cell engagers, and autologous transplants.
The Fellow on CallThe Fellow on Call | October 23, 2023
The Fellow on Call team discusses the management of advanced-stage DLBCL, including the role of CNS prophylaxis and more.
The Fellow on CallThe Fellow on Call | October 19, 2023
The Fellow on Call group discusses the early management of diffuse large B-cell lymphoma.
Oncology BrothersOncology Brothers | October 19, 2023
Dr. Patel joins The Oncology Brothers to discuss in-depth how to treat cutaneous melanoma using a treatment algorithm.
Rob DillardAtherosclerotic Disease | October 16, 2023
A cardio-oncology rehabilitation program can benefit cancer survivors at high risk of cardiovascular disease.
Rob DillardSkin Cancer | October 16, 2023
Nonmelanoma skin cancer is responsible for more deaths worldwide than melanoma, the more serious form of skin cancer.
Healthcare UnfilteredHealthcare Unfiltered | October 13, 2023
Shelly Rosenfeld discusses the intersection between medical and legal concerns in cancer care.
Rob DillardBreast Cancer | October 10, 2023
Dan Forche, CEO of PreludeDx, a leader in precision medicine for early-stage breast cancer, discusses DCISionRT.
Advertisement
Advertisement
Advertisement
Latest News

December 5, 2023